How should rabbit antithymocyte globulin (ATG) be dosed, administered, monitored, and what alternatives are available as induction therapy after cardiac transplantation?

Rabbit Antithymocyte Globulin (ATG) in Cardiac Transplantation

For antibody-mediated rejection (AMR) with hemodynamic compromise after cardiac transplantation, administer rabbit ATG at 1.5 mg/kg IV daily for 3 consecutive days as part of a multimodal regimen including plasmapheresis, high-dose corticosteroids, IVIg, and rituximab. 11

Indication & Clinical Context

ATG is reserved for severe AMR with hemodynamic compromise rather than routine induction therapy in cardiac transplantation. 11 The American Heart Association classifies ATG-containing AMR regimens as Class IIa, Level B evidence, meaning it is reasonable to use but lacks robust randomized trial data. 1

When to Use ATG in AMR Treatment

• Hemodynamically compromised patients with pAMR3 or pAMR2 with graft dysfunction require ATG as part of intensive therapy. 1
• Stanford protocols specifically recommend considering ATG in severe hemodynamic compromise scenarios. 1
• St. Louis Children's Hospital protocols use ATG for hemodynamically compromising rejection as part of T-cell depletion strategy. 1

Dosing & Administration Protocol

Standard Adult Dosing

• 1.5 mg/kg IV daily for 3 consecutive days with plasmapheresis in severe hemodynamic compromise. 1
• Administer through a central venous line to minimize infusion reactions. 22

Pediatric Dosing (St. Louis Protocol)

• 1.5 mg/kg IV daily for 5–7 days (total of 5–7 doses). 1
• First dose infused over at least 6 hours; subsequent doses may be given over 4 hours if administered through central line. 1

Infusion Rate Guidance (from FDA labeling)

• Start at 0.125 mL/kg/hr for 1 hour, then increase to 0.25 mL/kg/hr for 1 hour, then 0.35 mg/kg/hr for remainder of infusion (approximately 12 hours total). 22

Premedication Requirements

Mandatory premedications 30–60 minutes before each ATG dose:

• Methylprednisolone 2 mg/kg IV (or 20 mg/kg in pediatrics, maximum 1 g). 12
• Diphenhydramine 0.5 mg/kg IV (or 1 mg/kg in pediatrics). 12
• Acetaminophen 10–15 mg/kg IV or PO. 12

Complete AMR Treatment Algorithm with ATG

For Hemodynamically Compromised AMR (Stanford/Cedars-Sinai Protocols)

1. Day 1–3: High-dose corticosteroids

   • Methylprednisolone 500–1000 mg IV daily × 3 days. 11

2. Day 1–3: Rabbit ATG

   • 1.5 mg/kg IV daily × 3 days with premedications. 1

3. Plasmapheresis

   • Daily or every other day for minimum 5 sessions. 1
   • Perform 2× volume exchange. 1

4. IVIg

   • 2 g/kg total dose divided over 2 consecutive days immediately after plasmapheresis. 1
   • Administer on days 1–2 and days 29–30; re-dose monthly based on response. 1

5. Rituximab

   • 1 g IV on days 7 and 22 (or 375 mg/m² in smaller patients). 11

6. Refractory cases: Add bortezomib

   • 1.3 mg/m² on days 1,4,7, and 10. 11

Monitoring Requirements

Laboratory Monitoring

• Absolute lymphocyte count should fall to <200 cells/µL within 10 days of ATG initiation. 3
• CD3+ T-cell counts can be monitored to guide dosing; target <25 cells/µL for optimal immunosuppression. 4
• However, T-cell markers do not reliably predict subsequent rejection after ATG therapy. 5

Clinical Monitoring

• Echocardiogram and ECG on admission before initiating therapy. 1
• Donor-specific antibodies (DSA) drawn before therapy initiation. 1
• Endomyocardial biopsy for histology and C4d staining within 24 hours. 1
• Right heart catheterization within 24 hours to assess hemodynamics. 1

Infection Surveillance

• Cytomegalovirus (CMV) prophylaxis is mandatory with ATG use. 3
• Monitor for opportunistic infections, particularly in first 3 months post-treatment. 6
• Freedom from CMV infection at 5 years is 92–94% with appropriate prophylaxis. 3

Important Caveats & Pitfalls

C4d Deposition Artifact

ATG itself causes C4d deposition in myocardial capillaries independent of true AMR. 7 In pediatric cardiac transplants receiving ATG induction, 50% show C4d positivity on first biopsy versus 0% with basiliximab. 7 This artifact can persist up to 1 year post-transplant and must not be misinterpreted as AMR in the absence of histologic features and DSA. 7

Renal Function Considerations

• Baseline creatinine typically rises from 1.3 ± 0.8 mg/dL pre-transplant to 1.8 ± 0.9 mg/dL post-transplant, then improves to 1.0 ± 0.4 mg/dL at discharge. 3
• ATG may benefit renal function by delaying calcineurin inhibitor exposure during the immediate post-transplant period. 3
• Initiation of cyclosporine may be delayed prior to ATG to preserve renal function. 2

Infection Risk

• No increased CMV infection rate when appropriate prophylaxis is used (CMV infection rates 20–35% across ATG doses). 8
• Severe infection incidence at 10 years is dose-dependent: 37% with <4.5 mg/kg total dose, 23% with 4.5–7.5 mg/kg, and 45% with >7.5 mg/kg. 8

Malignancy Risk

• Rate of malignancy (excluding skin cancer) is 6–8% at 5 years, with higher rates at cumulative doses >4.5 mg/kg (13.85–14.95 per 1000 patient-years versus 7.83 per 1000 patient-years). 83

Alternative Therapies for AMR

When ATG is Not Indicated (pAMR2 without dysfunction)

• Pulse corticosteroids only for pAMR2 without graft dysfunction or DSA. 1

For High-Risk Patients Without Hemodynamic Compromise

• IVIg or rituximab infusion for positive DSA or allosensitized patients. 1

Refractory AMR Options

• Photopheresis for refractory cases (covered by Medicare for refractory cardiac allograft rejection). 1
• Total lymphoid irradiation (TLI) as salvage therapy. 1
• Bortezomib 1.3 mg/m² on days 1,4,8, and 11 for plasma cell-targeted therapy. 1

Evidence Quality & Limitations

There are no randomized controlled trials of ATG for AMR treatment; all recommendations derive from case series, retrospective studies, and expert consensus (Level C evidence). 1 The protocols presented represent institutional experience from high-volume centers (Stanford, Cedars-Sinai, Cleveland Clinic, St. Louis Children's Hospital) published in the 2015 American Heart Association scientific statement. 11

For induction therapy (distinct from AMR treatment), retrospective data suggest a cumulative dose of 4.5–7.5 mg/kg total offers the best risk-benefit ratio, with lower rejection rates than <4.5 mg/kg and fewer infections than >7.5 mg/kg. 8 However, a 2022 study found no difference in rejection or mortality between 4.5 mg/kg and <4.5 mg/kg induction doses. 6